Do you want to read an article? Please log in or register.
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up
Breast Cancer
Related content
Breast Cancer
Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database
Eur J Cancer
Aristei C, Tomatis M, Ponti A, Marotti L, Battisti NML, Leung Cheung K, Hartmann OJ, Rubio IT, Santini D, Sardanelli F, Senkus E, van Dam P, Curigliano G, Eusoma Working Group
doi: 10.1016/j.ejca.2026.116259
Breast Cancer
Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity
Int J Cancer
Nordenskjöld AE, Ríos-Romero M, Dar H, Fornander T, Perez-Tenorio G, Fohlin H, Stål O, Tutzauer J, Lindström LS
doi: 10.1002/ijc.70409
RECOMMENDED
Breast Cancer
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
★ 1
Recommended by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Valenza C, Zheng Y, Milano M, Trapani D, Giordano E, Guidi L, Berton Giachetti PPM, Boldrini L, Castellano G, Katrini J, Malagutti B, Antonarelli G, Conforti F, Pagan E, Bagnardi V, Kirkner GJ, Sangalli C, Dibble KE, Colleoni M, Regan MM, Munzone E, Curigliano G, Partridge AH
doi: 10.1200/JCO-25-01660
ESMO 2025
Breast Cancer
NATALEE: Ribociclib plus adjuvant endocrine therapy sustains iDFS benefit two years post-treatment in patients with HR+/HER2− breast cancer
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Breast Cancer
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group
Lancet Oncol
Jensen MB, Torpe E, Teunissen Z, Taarnhøj G, Brix E, Knoop A, Yammeni S, Donskov F, Ejlertsen B
doi: 10.1016/S1470-2045(25)00085-3
RECOMMENDED
Breast Cancer
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
O'Brien KM, House MG, Goldberg M, Jones ME, Weinberg CR, de Gonzalez AB, Bertrand KA, Blot WJ, DeHart JC, Couch FJ, Garcia-Closas M, Giles GG, Kirsh VA, Kitahara CM, Koh WP, Park HL, Milne RL, Palmer JR, Patel AV, Rohan TE, Schoemaker MJ, Swerdlow AJ, Teras LR, Vachon C, Visvanathan K, Yuan JM, Zheng W, Nichols HB, Sandler DP
doi: 10.1016/S1470-2045(25)00211-6